[Skip to Navigation]
Comment & Response
March 2015

Indications and Limitations of Afamelanotide for Treating Vitiligo

Author Affiliations
  • 1Department of Dermatology, University Hospital of Nice, Nice, France
JAMA Dermatol. 2015;151(3):349-350. doi:10.1001/jamadermatol.2014.4848

To the Editor I read with great interest the study by Lim et al1 on the use of afamelanotide in combination with narrowband UV-B for treating vitiligo. So far, there is no truly satisfactory treatment for vitiligo, so any new approach is most welcome. However, this study raises several issues. Afamelanotide binds with the melanocortin-1 receptor (MC1R), which is the receptor upstream of one of the key pathways for melanogenesis.2 Unfortunately, MC1R is not expressed by melanocyte stem cells, and thus afamelanotide can stimulate pigmentation and increase proliferation of melanocytes but cannot have any effect on the differentiation of melanocyte stem cells.3

Add or change institution